secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2024-10-30T23:59:59+00:00
Accession:  0001437749-24-032613
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences Q3 net loss $12.7M; appoints Dr. Kenigsberg as CMO for Electrophysiology
--------------------------------------------------------------------------------

- GAAP net loss $12.7M in Q3 2024 vs $10.6M in Q3 2023; cash $79M including $60M rights offering.
- Placed nsPFA Percutaneous Electrode System at 7 US pilot sites; pivotal trial for thyroid nodules expected mid-2025.
- Over 50 patients treated with nano-PFA 360 catheter in European feasibility study; two additional study sites engaged.
- Appointed Dr. David Kenigsberg as CMO of Electrophysiology; added Dr. Andrea Natale as medical advisor.
- Cash burn $8.5M in Q3; warrants could raise up to $66M at $11/share, exercisable immediately.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924032613/0001437749-24-032613-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774924032613/plse20241028_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-032613

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer